# First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors

> **NCT01110083** · PHASE1 · TERMINATED · sponsor: **EMD Serono** · enrollment: 38 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** EMD 1204831

## Key facts

- **NCT ID:** NCT01110083
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04
- **Primary completion:** 2012-03
- **Final completion:** —
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** Please see "Purpose" statement below.
- **Last updated:** 2013-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01110083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01110083, "First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01110083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*